Merck Patent Gmbh

Dana-farber-cancer Institute Inc.

Emory University

Medarex Inc.

Medtronic, Inc.

Cornell Research Foundation Inc.

Research Corporation Technologies, Inc.

Biovation Limited

Agen Biomedical Ltd.

Micromet Ag

Vasgene Therapeutics, Inc

C2n Diagnostics LLC

Famewave Ltd.

Antitope Limited

Francis J Carr

Timothy David Jones

James Peter Gregson

Stephen Williams

Gordon James Freeman

Rafi Ahmed

Anita Anne Hamilton

Matthew Baker

Koen Hellendoorn

David J King

Christopher Robert Bebbington

Josephine M Cardarelli

Sarah Lee Pogue

Jeannick Cizeau

Glen MacDonald

Nicholas Ronald Glover

Tim Jones

Joycelyn Entwistle

Tseng-hui Timothy Chen

Denis Georges Bosc

Neil H Bander

Richard William Titball

Lisa Lynn Shafer

Kurt R Gehlsen

Dawn Ann Bembridge

Arron Hearn

Stephen D Gillies

Diljeet Singh Athwal

Parkash S Gill

Robert Hofmeister

Robert George Edward Holgate

Graham Carter

Yair Sapir

Valery Krasnoperov

Tehila Ben-Moshe

Gal Markel

Jacob Schachter

Ilana Mandel

Rona Ortenberg

Birgit Kohleisen

Patrick Bäuerle

Ulla Lenkkeri-Schütz

Christian Itin

Tim West

Robert George E Holgate

Simon William Keen

Graham Garter

David King

Mathew Baker

Alyson Rust

Laura Davies

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Polynucleotides encoding humanized antibodies against CEACAM1

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

The present application relates to modified T cell epitopes derived from fungal ribotoxins, including &#x3b1;-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.

Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.

Humanized anti-tau antibodies

The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.

Human anti-PD-1 antibodies and uses therefor

In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes.

Cancer treatment using humanized antibodies that bind to EphB4

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.

Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)

The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Cytotoxins comprising modified bouganin toxin for the treatment of cancer

Humanized anti-A&#x3b2; antibodies derived from a murine antibody directed to a N-terminal epitope of A&#x3b2; are described. The humanized antibodies have reduced or no human T cell epitopes and bind A&#x3b2; with an affinity similar to that of the murine antibody.

Humanized anti-amyloid beta antibodies

Anti-PD-L1 antibodies and uses therefor

A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.

CD20-binding polypeptide compositions for treating autoimmune disease

The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.

Multispecfic deimmunized CD3-binders

Growing community of inventors

Aberdeenshire, United Kingdom

Francis J Carr